Liu, Wenli http://orcid.org/0000-0002-1981-611X
Yalcinkaya, Mustafa
Maestre, Inés Fernández
Olszewska, Malgorzata
Ampomah, Patrick B.
Heimlich, J. Brett
Wang, Ranran
Vela, Pablo Sánchez http://orcid.org/0000-0002-9286-8290
Xiao, Tong http://orcid.org/0000-0003-1462-4650
Bick, Alexander G. http://orcid.org/0000-0001-5824-9595
Levine, Ross http://orcid.org/0000-0002-7884-1905
Papapetrou, Eirini P.
Libby, Peter http://orcid.org/0000-0002-1502-502X
Tabas, Ira
Wang, Nan http://orcid.org/0000-0001-9976-0859
Tall, Alan R. http://orcid.org/0000-0002-7708-2417
Article History
Received: 18 August 2022
Accepted: 2 May 2023
First Online: 8 June 2023
Competing interests
: A.R.T. is a consultant for Amgen, CSL Behring, AstraZeneca and Foresite Laboratories, and is on the scientific advisory board of Staten Biotechnology, Fortico Biotech and Beren Therapeutics. P.L. is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, MedImmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer and Sanofi Regeneron. P.L. is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Elucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, MedImmune, Novartis, PlaqueTec, TenSixteen Bio, Soley Thereapeutics and XBiotech. His laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk and Genentech. P.L. is on the board of directors of XBiotech. He has a financial interest in XBiotech, a company developing therapeutic human antibodies, in TenSixteen Bio, a company targeting somatic mosaicism and CHIP to discover and develop new therapeutics to treat age-related diseases, and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection to discover and develop new drugs, currently focusing on cancer therapeutics. His interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. The other authors declare no competing interests.